Atsuto Mouri

4PUBLICATIONS
46CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|May 26, 2026
Sequential Immune Activation of Effector T Cells as Biomarkers of Response to Durvalumab in patients with locally advanced NSCLC.

|Apr 18, 2025
A Real-Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune-Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolumab Plus Ipilimumab.

Atsuto Mouri, Hisao Imai, Satoshi Endo

|Oct 11, 2024
Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.

Hidetoshi Hayashi, Makoto Nishio, Hiroaki Akamatsu

|Oct 11, 2022
Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy.

Hiroshi Kagamu, Satoshi Yamasaki, Shigehisa Kitano

Pageof 1

Frequent Collaborators

2 joint publications

Hiroshi Kagamu

2 joint publications

Masaki Fujita

2 joint publications

Shigehisa Kitano

2 joint publications

Ou Yamaguchi